Opioid Use Disorder Drugs Market to Grow with a CAGR of 9.26% through 2030
Expansion
of government initiatives to curb opioid abuse and growing availability of
novel therapies for opioid addiction, is expected to
drive the Global Opioid Use Disorder Drugs Market growth in the forecast
period, 2026-2030
According to
TechSci Research report, “Opioid Use Disorder Drugs Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Opioid Use Disorder Drugs Market stood at USD 3.87 Billion in
2024 and is expected to reach USD 6.59 Billion by 2030 with a CAGR of 9.26% during
the forecast period. The Global Opioid Use Disorder (OUD) Drugs Market is
witnessing unprecedented growth driven by a convergence of factors that
collectively address one of the most pressing public health crises of our time:
opioid addiction. With opioid misuse and overdose-related deaths reaching
alarming proportions worldwide, the demand for effective treatments is higher
than ever before. The primary driver fueling the growth of the Global
OUD Drugs Market is the escalating opioid epidemic. Opioid addiction has become
a global crisis, with millions of individuals struggling with dependence on
prescription opioids or illicit drugs like heroin. The sheer scale of this
epidemic has led to increased recognition of the need for comprehensive
treatment solutions, thereby driving the demand for OUD drugs. Heightened
public awareness and education campaigns have played a pivotal role in boosting
the OUD Drugs Market. Governments, non-profit organizations, and healthcare
providers have been working tirelessly to educate the public about the risks
associated with opioids and the availability of effective treatments. As
individuals become more informed about OUD and its treatment options, the demand
for OUD drugs has increased.
Governments across the globe have recognized the
severity of the opioid crisis and have responded with substantial funding and
policy support. These initiatives include expanding access to OUD medications,
reducing stigma associated with addiction, and improving healthcare
infrastructure for addiction treatment. The financial support provided by
governments has significantly expanded the OUD Drugs Market. The development of
innovative and effective treatment options has been a major driver of market
growth. OUD drugs can be categorized into three main classes: opioid agonists,
partial agonists, and antagonists. New medications with improved efficacy and
safety profiles continue to emerge. For example, extended-release formulations
of buprenorphine, such as Sublocade and Probuphine, offer long-lasting relief
from withdrawal symptoms, reducing the burden on patients to take daily
medications. Research and development efforts within the pharmaceutical
industry are dedicated to creating better and more accessible OUD drugs. These
efforts are focused on developing new formulations, improving drug delivery
mechanisms, and investigating novel medications. As science advances and
understanding of addiction deepens, the market benefits from the development of
more potent and targeted drugs.
The COVID-19 pandemic accelerated the adoption of telemedicine and telehealth services, which has positively impacted the OUD Drugs Market. Telehealth has made it easier for individuals with OUD to access healthcare professionals and receive prescriptions for necessary medications remotely. This increased accessibility has improved treatment adherence and outcomes. Reducing the stigma associated with addiction and addiction treatment has been a key driver for market growth. As societal attitudes evolve, more individuals are seeking help for OUD without fear of judgment or discrimination. The reduction of stigma has resulted in more people seeking treatment, thereby driving demand for OUD drugs.Furthermore, the integration of digital health technologies and telemedicine has expanded access to treatment and improved patient outcomes. Telehealth services have made it easier for individuals with OUD to connect with healthcare providers, receive prescriptions, and access counseling and support remotely. This has enhanced the overall treatment experience and increased the reach of OUD medications.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Opioid Use Disorder Drugs Market”
The Global Opioid Use Disorder Drugs Market is
segmented into drug type, route of administration, distribution channel, regional
distribution, and company.
Based on the Distribution
Channel, Online Pharmacies emerged as the fastest growing segment in the Global
Opioid Use Disorder Drugs Market during the forecast period. This is owing to
the increasing demand for accessible, discreet, and convenient treatment
options. The growing stigma associated with opioid addiction often prevents
individuals from seeking help through traditional in-person channels. Online
pharmacies help address this challenge by offering a more private and anonymous
way for patients to obtain necessary medications such as buprenorphine,
methadone, and naltrexone without the discomfort of public scrutiny. This
convenience has become a critical factor in expanding treatment adherence,
especially in underserved or remote regions where physical pharmacies may not
be easily accessible. The rapid digitalization of healthcare services and
increased smartphone and internet penetration, particularly in emerging
economies, have further propelled the growth of online pharmacies. Regulatory
advancements in telemedicine and e-prescriptions have enabled healthcare
professionals to conduct remote consultations and prescribe controlled
substances for OUD treatment in a compliant manner.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Opioid Use Disorder Drugs Market during
the forecast period. This is due to the rising prevalence, policy reforms and
improving healthcare access across emerging economies in Asia-Pacific are
contributing significantly to market growth. Several governments are
streamlining regulations to allow for greater availability of medication-assisted
treatment (MAT) options, including methadone and buprenorphine. This regulatory
relaxation, combined with the introduction of community-based rehabilitation
centers and mobile health services, is improving access to treatment in both
urban and rural regions. There is also a notable increase in partnerships
between public health agencies and pharmaceutical companies focused on
expanding research and localized clinical trials for OUD therapies.
Furthermore, growing investments in healthcare infrastructure and rising health
insurance penetration in countries such as Thailand, Malaysia, and Vietnam are
allowing broader segments of the population to afford addiction treatment. This
growing affordability and accessibility, coupled with the expanding efforts to
de-stigmatize addiction and promote mental health, are expected to propel the
adoption of OUD drugs in the region.
Major companies operating in Global Opioid Use
Disorder Drugs Market are:
- Mallinckrodt Pharmaceuticals
- Hikma Pharmaceuticals Inc
- Collegium Pharmaceutical, Inc.
- Braeburn, Inc.
- Purdue Pharma L.P.
- Curia Global Inc.
- EMERGENT
- Bristol-Myers Squibb, S.r.l
- Alkermes, Inc.
- Indivior Inc
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The Global
Opioid Use Disorder Drugs Market is expanding due to the growing integration of
long-acting injectable therapies into mainstream treatment protocols, which
significantly improves patient compliance and reduces relapse rates. Unlike
traditional daily oral medications, long-acting formulations such as
extended-release naltrexone or monthly buprenorphine injections offer sustained
therapeutic levels, minimizing the risk of missed doses and enhancing overall
treatment adherence. These therapies are increasingly preferred by clinicians
for their ability to reduce diversion and misuse, while also supporting
patients in maintaining long-term recovery. As more countries adopt these
innovative treatment strategies into public health programs and insurance
coverage expands, the demand for such advanced drug delivery methods continues
to grow.,” said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Opioid Use Disorder
Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Drug Type (Agonist Drugs, Antagonist Drugs, Others), By Route of
Administration (Oral, Parenteral, Sublingual, Nasal), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and
Competition, 2020-2030F”, has evaluated the future growth potential of Global
Opioid Use Disorder Drugs Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Opioid
Use Disorder Drugs Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com